Logo

BJDX

Bluejay Diagnostics, Inc.

BJDX

Bluejay Diagnostics, Inc. • NASDAQ
$1.32 ▼ -8.97% (-0.13)
Market Cap $2.39 M
52w High $10.20
52w Low $1.24
Dividend Yield 0%
P/E 0.01
Volume 316.92K
Outstanding Shares 1.81M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $1.617M ▼ $-1.598M ▲ 0% $-1.01 ▲ $-1.587M ▲
Q2-2025 $0 $1.985M ▲ $-1.957M ▼ 0% $-1.41 ▲ $-1.918M ▼
Q1-2025 $0 $1.889M ▲ $-1.864M ▼ 0% $-11.64 ▼ $-1.837M ▼
Q4-2024 $0 $1.485M ▲ $-1.432M ▲ 0% $-8.94 ▲ $-1.394M ▼
Q3-2024 $0 $1.362M $-1.482M 0% $-9.25 $-1.238M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $3.082M ▼ $4.89M ▼ $1.197M ▲ $3.693M ▼
Q2-2025 $4.443M ▲ $6.403M ▲ $1.113M ▼ $5.29M ▲
Q1-2025 $3.116M ▼ $5.278M ▼ $1.412M ▲ $3.866M ▼
Q4-2024 $4.302M ▼ $6.657M ▼ $927.924K ▼ $5.729M ▼
Q3-2024 $5.756M $8.353M $1.189M $7.164M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.598M ▲ $-1.36M ▲ $0 $-1.015K ▼ $-1.361M ▼ $-1.36M ▲
Q2-2025 $-1.957M ▼ $-2.054M ▼ $0 $3.381M ▲ $1.327M ▲ $-2.054M ▼
Q1-2025 $-1.864M ▼ $-1.185M ▲ $0 ▲ $-985 ▼ $-1.186M ▲ $-1.185M ▲
Q4-2024 $-1.432M ▲ $-1.739M ▲ $-1.125K ▼ $286.015K ▲ $-1.454M ▲ $-1.74M ▲
Q3-2024 $-1.482M $-1.866M $-227 $-436.255K $-2.303M $-1.866M

Five-Year Company Overview

Income Statement

Income Statement Bluejay is still a pre‑revenue company. It has not generated meaningful sales over the past several years, while operating expenses continue to create steady losses. These losses appear relatively small in absolute corporate terms but are large compared with the company’s tiny size. The very large negative earnings per share values mostly reflect repeated reverse stock splits and share-count changes rather than a sudden change in the underlying business. Overall, the income statement shows a classic early‑stage R&D profile: spending money to develop products without any commercial revenue to offset costs yet.

Balance Sheet

Balance Sheet The balance sheet is extremely light. The company reports only a small base of total assets and cash, matched by a similarly small level of equity, and essentially no debt. This means Bluejay does not appear to be heavily leveraged, but it also has a very limited financial cushion. The repeated reverse stock splits suggest substantial past dilution and challenges maintaining its market listing. Going forward, its very small asset and cash position signals a strong dependence on raising new capital to fund operations and trials.

Cash Flow

Cash Flow Cash flows from operations have been consistently negative, which is typical for a development‑stage healthcare company without product revenue. There is little to no spending on long‑term assets, so the main cash use is simply running the business and advancing the pipeline. With no internal cash generation, Bluejay’s ability to continue funding its plans will likely depend on external financing, such as equity raises or partnerships. The current pattern shows ongoing cash burn with no offsetting inflows from product sales yet.

Competitive Edge

Competitive Edge Bluejay operates in the highly competitive medical diagnostics space, where large, well‑funded companies dominate hospital labs and point‑of‑care testing. Its differentiation centers on the Symphony System: rapid, near‑patient testing with a simple workflow and a focus on severe conditions like sepsis. Proprietary and licensed technology, plus an exclusive manufacturing partnership, provide some protection and scalability advantages. However, the company’s tiny scale, lack of commercial track record, and the presence of established diagnostics players make its ultimate market position uncertain and execution‑dependent.

Innovation and R&D

Innovation and R&D Innovation is the clear centerpiece of Bluejay’s story. The Symphony platform combines microfluidics, nanotechnology, and established immunoassay methods to deliver fast, quantitative results from whole blood near the patient. The lead IL‑6 sepsis test, supported by early clinical data and a pivotal trial in progress, aims to address a real unmet need in critical care. The choice of a more streamlined FDA pathway and the vision for future test panels (for multiple critical‑care markers and potentially chest‑pain evaluation) show a platform strategy rather than a one‑off product. That said, timelines extend several years, and all of this depends on successful trials, regulatory clearance, and adequate funding.

Summary

Bluejay Diagnostics is an early‑stage, pre‑revenue diagnostics company built around a promising near‑patient testing platform but operating with very limited financial resources. The financial statements show no meaningful revenue, ongoing operating losses, and a very thin balance sheet with minimal cash and equity, implying a strong reliance on future capital raises. On the strategic side, the Symphony platform, IL‑6 sepsis test, intellectual property, and manufacturing partnership collectively form a credible innovation story in a large, clinically important market. The major uncertainties lie in clinical and regulatory outcomes, competitive response from larger diagnostics firms, and the company’s ability to consistently secure funding long enough to reach commercialization. Overall, this is a high‑risk, high‑uncertainty profile typical of a small, development‑stage healthcare technology company that is still several key milestones away from a proven commercial business.

NEWS

October 10, 2025 · 5:16 PM UTC

Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Read more

October 9, 2025 · 3:15 PM UTC

Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Read more

October 9, 2025 · 6:30 AM UTC

Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform

Read more